Detail of "191114-48-4"

Reference

Enhanced recovery following ocular surgery

All Rights Reserved. Enhanced recovery following ocular surgery. Peyman, Gholam A. (USA ). U.S. Pat.There are some reagents with their cas registry numbers 191114-48-4 and 143375-33-1 are used in this study. Appl. Publ. US 2007014760 A1 18 Jan 2007,7pp. (English). (United States of America). CODEN: USXXCO. INCL: 424085100; 514011000; 514012000; 514028000; 514029000; 514291000; 424428000; 514171000; 514165000; 514570000. APPLICATION: US 2005-183355 18 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 2, 15 An ocular method comprising localized ocular administration of a pharmaceutically acceptable formulation and effective concn. of at least one neuro-stimulatory agent, which may include a macrolide, for a duration sufficient to at least partially restore corneal sensation, or at least one macrolide to reduce scarring after ocular surgery. The neuro-stimulatory agent may be one or more of a macrolide, macrolide analog, neurotrophin, or neuropoietic factor. The method is used in a patent following ocular surgery, such as vision-correction surgery, glaucoma surgery, or retinal detachment repair surgery. .

Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia

All Rights Reserved. Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. Zhanel, George G.; Hisanaga, Tamiko; Wierzbowski, Aleksandra; Hoban, Daryl J. (Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Can.). Therapeutics and Clinical Risk Management, 2(1), 59-75 (English) 2006 Dove Medical Press (NZ) Ltd. CODEN: TCRMA6. ISSN: 1176-6336. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), and community-acquired pneumonia (CAP) are common conditions and constitute a substantial socioeconomic burden. The ketolides are a new class of antibacterials with a targeted spectrum of antibacterial activity. In vitro, telithromycin is active against common bacterial pathogens that cause upper and lower respiratory tract infections, including some isolates that are resistant to other antibiotic classes. 191114-48-4 which is the cas registry number of some chemical is mentioned. In 2004, telithromycin was the first ketolide antibiotic approved for clin. use by the US Food and Drug Administration for the treatment of adult outpatients with ABS, AECB, and mild-to-moderate CAP. This review discusses the use of telithromycin in the treatment of these infections, providing an overview of its antibacterial activity, pharmacokinetic and pharmacodynamic properties, clin. efficacy, and tolerability-safety, and concludes that telithromycin is an appropriate option for the treatment of community-acquired ABS, AECB, and mild-to-moderate CAP. .